“…WIN, having been briefly investigated as a potential male contraceptive (Heller et al, 1961), was shown to be a potent inducer of congenital heart defects including coronary defects, yet, the cause for such defects remains poorly understood (Oster et al, 1974; Kilburn et al, 1982; Binder, 1985; Tasaka et al, 1991; Ito et al, 1992; Okishima et al, 1992; Kuribayashi and Roberts, 1993; Jackson et al, 1995; Nishijima et al, 2000; Okamoto et al, 2004; Fujino et al, 2005; Kise et al, 2005; Hanato et al, 2011). We found that administration of WIN between E9.5 and E13.5 dramatically reduced the amount of RA and alters RA-signaling in developing mouse embryos and their hearts (Wang et al, 2018).…”